title: Transdermal delivery of bioidentical progesterone using dutasteride (A 5α-reductase inhibitor): a pilot study.
abstract: OBJECTIVE
  Bioavailability of transdermal progesterone is low and variable. This may be attributed to transdermal metabolism by the 5α-reductase enzymes or the direct transport to the saliva. The objective of the current study was to evaluate the effect of enzyme inhibition on the bioavailability of transdermal progesterone. Serum and salivary progesterone levels were evaluated to gain a better insight into the mechanism progesterone transport across the skin.
  
  
  METHODS
  Twenty postmenopausal women with a Follicle Stimulating Hormone > 40IU/L were recruited to take part in the study. The subjects were randomly allocated to either dutasteride (n=10) or placebo (n=10). Each group applied either 500 mg of non ionic cream or dutasteride cream (2mg/g) to the right arm for 2 weeks. This was followed by applying 500 mg of progesterone or progesterone dutasteride cream (equivalent to 40 mg of progesterone) for a further 2 weeks. On day 30 blood and saliva were collected for over 12 hours and progesterone concentration was measured.
  
  
  RESULTS
  The baseline progesterone concentration on day zero was 0.1 ng/ml. On day 30 baseline progesterone levels increased significantly (p <0.05) to 1.40 ng/ml and 1.15 ng/ml in the progesterone and dutasteride groups, respectively. Salivary progesterone concentrations were increased by seven fold, from 0.40 ng/ml to 2.9 ng/ml. On average, salivary progesterone concentration was four times the serum levels.
  
  
  CONCLUSIONS
  The average serum and salivary progesterone concentration, Cmax, and the AUC were slightly higher in the dutasteride group, but no significant difference could be noted. Metabolism by the 5α-reductase enzyme is unlikely to affect the bioavailability of progesterone.
authors.forename: Sara
authors.initials: S
authors.lastname: Zargar-Shoshtari
authors.forename: Hannaneh
authors.initials: H
authors.lastname: Wahhabaghei
authors.forename: Abdolrasoul
authors.initials: A
authors.lastname: Mehrsai
authors.forename: Jingyuan
authors.initials: J
authors.lastname: Wen
authors.forename: Raid
authors.initials: R
authors.lastname: Alany
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D019540:Area Under Curve; D001378:Azasteroids / Q000008:administration & dosage / Q000494:pharmacology*; D001682:Biological Availability; D004311:Double-Blind Method; D004338:Drug Combinations; D004347:Drug Interactions; D000068538:Dutasteride; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D017698:Postmenopause; D011374:Progesterone / Q000008:administration & dosage / Q000493:pharmacokinetics*; D011372:Progestins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D012463:Saliva / Q000737:chemistry
chemical_list: D058891:5-alpha Reductase Inhibitors; D001378:Azasteroids; D004338:Drug Combinations; D011372:Progestins; D011374:Progesterone; D005640:Follicle Stimulating Hormone; D000068538:Dutasteride